HIFU Sonablate 500 Prostate Cancer Treatment Device Presents Improved Performance
Published: May 23, 2005
Misonix, Inc. a developer of ultrasonic medical device technology for the treatment of cancer and other healthcare purposes, and Focus Surgery, Inc., a pioneering company in the field of High Intensity Focused Ultrasound (”HIFU”) with the most advanced and easy to use system in the field, today announced the development of new system capabilities designed to reduce impotence in men and shorten prostate treatment times with the Sonablate® 500, a device for the treatment of prostate cancer and benign prostatic hyperplasia (”BPH”). The Sonablate 500 along with its improved capabilities is being displayed at the American Urological Association’s 100th Annual Meeting in San Antonio, Texas this week.
Misonix is the exclusive distributor for the Sonablate 500 (”SB500″) in Europe and Russia. In addition, Misonix has an equity interest in Focus Surgery, manufactures its product and has an exclusive license to manufacture and sell a product using Focus Surgery’s High Intensity Focused Ultrasound throughout the world for the ablation of cancerous tissue in the kidney and liver.
The American Urological Association (”AUA”)’s Annual Meeting is the largest meeting of urologic professionals in the world. With more than 10,000 urologists and health-care professionals and 5,000 exhibitors in attendance, there is no better place to learn about the latest advances in urology. Urologists are one of several medical caregiver groups that work with patients diagnosed with prostate cancer. According to the AUA, prostate cancer is a significant health-care problem in the United States due to its high incidence. It is the most common cancer in men affecting approximately 200,000 American men each year with approximately 32,000 of these men dying each year.
The improved capabilities of the SB500 include new software and hardware using Doppler ultrasound to detect the neurovascular bundles controlling erectile function, advanced 3D imaging, and intensive energy delivery cycles with remote access capabilities. The addition of Doppler ultrasound enables the physician to detect the neurovascular bundles for potency preservation during prostate cancer treatment. The 3D imaging software converts the SB500 ultrasound images into 3D model. The physician is then able to rotate, slice and separate prostate from the surrounding tissue for accurate HIFU treatment. The remote access software allows monitoring the SB500 usage from a distant location. “Focus Surgery continues to lead the way in the development of HIFU technology,” said Narendra T. Sanghvi, President and CEO of Focus Surgery, Inc. “We are working to improve the quality of life of the patients who are treated with the Sonablate 500. These novel additions to the Sonablate 500 will help physicians improve the treatment outcome.”
The SB 500 is approved for use in many countries and is distributed by the major shareholders of Focus Surgery, Inc. These shareholders/distributors include Takai Hospital Supply of Japan in Asia, USHIFU of Charlotte, NC in the Americas, and Misonix in Europe and Russia. In addition, Misonix manufactures the SB500 and has an exclusive license to manufacture and sell a product using Focus Surgery’s High Intensity Focused Ultrasound throughout the world for the ablation of cancerous tissue in the kidney and liver.
About Focus Surgery, Inc.
Focus Surgery, Inc. pioneers the development and commercialization of products using High Intensity Focused Ultrasound (HIFU) for the treatment of soft tissue diseases. Focus Surgery designs the Sonablate® 500 system, an image-guided acoustic ablation device. Doctors worldwide have successfully treated over 3,500 prostate disease patients using the SB500. Focus Surgery maintains an internationally accredited Quality System which has achieved ISO 9001/2000 and ISO 13485/1996 certifications. The Sonablate® 500 has the CE Mark for the treatment of prostate diseases and is approved in Europe and other countries. The SB500 is approved by the FDA as an investigational device for clinical trials which are currently ongoing in the United States.
If you enjoyed this good news Subscribe to Good News Blog
Share this
To share this simply copy and paste one of the below URL's: